Abstract
Objective and Design: There is crucial evidence that leukotrienes are significant mediators of inflammation in inflammatory bowel diseases (IBD). Thus, selective inhibition of leukotriene synthesis is believed to provide a novel approach to therapy of IBD. The aim of the study is to study the efficacy of a potent 5-lipoxygenase activating protein inhibitor (FLAP), BAY y 1015 in a dextran sulfate model of mouse colitis.¶Material: Outbred female mice weighing approximately 25 grams were used to produce acute or chronic colitis by feeding 5% dextran sulfate in drinking water.¶Treatment: Colitic mice were treated with placebo (3% starch suspension, 0.1 ml. p.o., bid) or BAY y 1015 at 8 or 24 mg/kg, p.o., bid or olsalazine, 150 mg/kg/day, p.o.¶Methods: Efficacy was determined by measuring daily disease activity index (DAI), quantitative histological scores, qualitative histology and measurement of tissue myeloperoxidase (MPO) and leukotriene B4 (LTB4) levels.¶Results: BAY y 1015 was significantly more effective in improving the qualitative histology, inhibiting the DAI, inflammation scores (37–79%), crypt scores (28–71%), MPO (49–57%) and LTB4 levels (56–63%) compared to placebo treatment at all levels of colitis. The two doses of BAY y 1015 were equipotent in decreasing TLB4 levels. BAY y 1015 was significantly better than olsalazine in two of the three protocols used in this study. In the advanced disease level both doses of BAY y 1015 were equipotent in inhibiting crypt and (28–32%) inflammation scores (34–36%), LTB4 (34–56%) and MPO 41–49%) compared to olsalazine.¶Conclusion: This study suggests the possibility of investigating the use of this compound for the treatment of human inflammatory bowel diseases.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 19 July 1995; returned for revision 31 August 1995; returned for final revision 12 March 1997; accepted by G. W. Carter 1 April 1997
Rights and permissions
About this article
Cite this article
Murthy, S., Murthy, N., Coppola, D. et al. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis. Inflamm. res. 46, 224–233 (1997). https://doi.org/10.1007/s000110050177
Published:
Issue Date:
DOI: https://doi.org/10.1007/s000110050177